Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Therapeutic potential of s-cdcs in myocardial infarction: interactions with standard drugs

Therapeutic potential of s-cdcs in myocardial infarction: interactions with standard drugs IntroductionMyocardial infarction (MI) remains a leading global cause of mortality and is commonly treated with Captopril, Spironolactone, and Bisoprolol. Emerging therapies, such as the secretome derived from cardiosphere-derived cells (S-CDCs), have shown potential in reducing MI scar size. This study aims to evaluate the potential therapeutic implications of S-CDCs in MI treatment, particularly in relation to the aforementioned standard drugs.MethodsCDCs (n = 4) were isolated from cardiac explants of Large White pigs and cultured in DMEM with 1% ITS and antibiotics for four days. The conditioned medium was centrifuged and ultrafiltered (3 kDa) to obtain the S-CDCs. The content of S-CDCs, including miRNAs and genes, was analysed using transcriptomic and qPCR techniques. Bioinformatics tools were used to establish the interaction network (IN) of Captopril, Bisoprolol, and Spironolactone with their target genes through the String app within Cytoscape. miRTargetLink 2.0 was used to predict miRNA-gene interactions, and FunRich analysed the gene network. Finally, the content of S-CDCs was compared with previously identified miRNAs and genes, and an interaction network was generated using Cytoscape.ResultsOur findings show that S-CDCs contain six miRNAs that interact with target genes of Captopril and Spironolactone. Additionally, S-CDCs harbor genes that interact with those affected by the drugs, with a predominant influence from Spironolactone.ConclusionS-CDCs may mimic the effects of Captopril and Spironolactone, potentially simplifying MI treatment. However, further studies are necessary to validate these findings. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Surgery Oxford University Press

Therapeutic potential of s-cdcs in myocardial infarction: interactions with standard drugs

Download PDF
2 pages

Loading next page...
 
/lp/oxford-university-press/therapeutic-potential-of-s-cdcs-in-myocardial-infarction-interactions-PqiR4kfeYP

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
ISSN
0007-1323
eISSN
1365-2168
DOI
10.1093/bjs/znae322.028
Publisher site
See Article on Publisher Site

Abstract

IntroductionMyocardial infarction (MI) remains a leading global cause of mortality and is commonly treated with Captopril, Spironolactone, and Bisoprolol. Emerging therapies, such as the secretome derived from cardiosphere-derived cells (S-CDCs), have shown potential in reducing MI scar size. This study aims to evaluate the potential therapeutic implications of S-CDCs in MI treatment, particularly in relation to the aforementioned standard drugs.MethodsCDCs (n = 4) were isolated from cardiac explants of Large White pigs and cultured in DMEM with 1% ITS and antibiotics for four days. The conditioned medium was centrifuged and ultrafiltered (3 kDa) to obtain the S-CDCs. The content of S-CDCs, including miRNAs and genes, was analysed using transcriptomic and qPCR techniques. Bioinformatics tools were used to establish the interaction network (IN) of Captopril, Bisoprolol, and Spironolactone with their target genes through the String app within Cytoscape. miRTargetLink 2.0 was used to predict miRNA-gene interactions, and FunRich analysed the gene network. Finally, the content of S-CDCs was compared with previously identified miRNAs and genes, and an interaction network was generated using Cytoscape.ResultsOur findings show that S-CDCs contain six miRNAs that interact with target genes of Captopril and Spironolactone. Additionally, S-CDCs harbor genes that interact with those affected by the drugs, with a predominant influence from Spironolactone.ConclusionS-CDCs may mimic the effects of Captopril and Spironolactone, potentially simplifying MI treatment. However, further studies are necessary to validate these findings.

Journal

British Journal of Surgery – Oxford University Press

Published: Jan 22, 2025

There are no references for this article.